Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by Hudson Valley Investment Advisors Inc. ADV

Hudson Valley Investment Advisors Inc. ADV decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 156,097 shares of the biopharmaceutical company's stock after selling 21,117 shares during the quarter. Hudson Valley Investment Advisors Inc. ADV's holdings in Pfizer were worth $4,141,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in PFE. Gladius Capital Management LP raised its position in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 38,015 shares during the period. Quarry LP purchased a new position in shares of Pfizer in the 2nd quarter worth $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Pfizer in the 3rd quarter worth $35,000. Joseph Group Capital Management raised its position in shares of Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 771 shares during the period. Finally, Strategic Financial Concepts LLC purchased a new position in shares of Pfizer in the 2nd quarter worth $38,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.5 %

NYSE:PFE traded down $0.13 during mid-day trading on Friday, reaching $26.73. The stock had a trading volume of 32,556,257 shares, compared to its average volume of 35,547,035. The company has a market capitalization of $151.48 billion, a price-to-earnings ratio of 36.12, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The stock's 50 day simple moving average is $26.18 and its two-hundred day simple moving average is $28.04. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the firm earned ($0.17) earnings per share. The company's revenue for the quarter was up 31.2% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.43%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's payout ratio is presently 232.43%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Wolfe Research assumed coverage on Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday. Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective on the stock. Guggenheim cut their price objective on Pfizer from $35.00 to $33.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Finally, Citigroup assumed coverage on Pfizer in a research report on Friday, October 25th. They issued a "neutral" rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $32.00.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.